Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
Canada
Princess Margaret Cancer Centre, Toronto, Ontario Last updated January 2026